Research programme: anticancer and autoimmune disorder therapeutics - Adendra Therapeutics
Latest Information Update: 20 Dec 2021
At a glance
- Originator Adendra Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Immunomodulators; T lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Autoimmune disorders; Solid tumours
Most Recent Events
- 07 Dec 2021 Research programme: anticancer and autoimmune disorder therapeutics - Adendra Therapeutics is available for licensing as of 07 Dec 2021. https://adendratx.com/about/ 9344155
- 07 Dec 2021 Early research in Autoimmune disorders in United Kingdom (unspecified route)
- 07 Dec 2021 Early research in Solid tumours in United Kingdom (unspecified route)